Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 140-144

  Foquet, Lander ^a   Hermsen, Cornelus C ^b   Van Gemert, Geert Jan ^b   Van Braeckel, Eva ^a   Weening, Karin E ^a   Sauerwein, Robert ^b   Meuleman, Philip ^a   Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; MONOCLONAL ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNITY; LIVER; MALARIA FALCIPARUM; MOSQUITO BITE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SPOROZOITE;

EID: 84892931367     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70349     Document Type: Article

References (39)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010; 6(1):90-96.
2. Rosenberg R, Wirtz RA, Schneider I, Burge R. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. Trans R Soc Trop Med Hyg. 1990;84(2):209-212.
3. Jin Y, Kebaier C, Vanderberg J. Direct microscopic quantification of dynamics of plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun. 2007;75(11):5532-5539.
4. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg. 2004; 71(2):196-201.
5. Meuleman P, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology. 2005;41(4):847-856.
6. Sacci JB Jr, et al. Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers. Int J Parasitol. 2006; 36(3):353-360.
7. Vaughan AM, et al. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest. 2012;122(10):3618-3628.
8. Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci U S A. 2007;104(51):20507-20511.
9. Azuma H, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007;25(8):903-910.
10. Mercer DF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001; 7(8):927-933.
11. Morosan S, et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J Infect Dis. 2006;193(7):996-1004.
12. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11(1):57-64.
13. Riley E, Stewart V. Immune mechanisms in malaria: new insights in vaccine development. Nat Med. 2013; 19(2):168-178.
14. Vekemans J, Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines. 2008;7(2):223-240.
15. Olotu A, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368(12):1111-1120.
16. RTS,S Clinical Trials Partnership, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367(24):2284-2295.
17. Bejon P, et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis. 2011; 204(1):9-18.
18. Casares S, Brumeanu TD, Richie TL. The RTS,S malaria vaccine. Vaccine. 2010;28(31):4880-4894.
19. Asante KP, et al. Safety and efficacy of the RTS, S/AS01 candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;(10):741-749.
20. Abdulla S, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008;359(24):2533-2544.
21. Kester KE, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/ AS01B RTS,S/AS02A in malaria-naive adults: safety, efficacy, immunologic associates of protection. J Infect Dis. 2009;200(3):337-346.
22. Aponte JJ, et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007; 370(9598):1543-1551.
23. Olotu A, et al. Efficacy of RTS,S/AS01E malaria vaccine exploratory analysis on anti-circumsporozoite antibody titres protection in children aged 5-17 months in Kenya Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011; 11(2):102-109.
24. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J. 2009;8:312.
25. Clement F, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J. 2012;11:384.
26. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun. 1986;51(3):859-864.
27. Amino R. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe. 2008;3(2):88-96.
28. House BL, Hollingdale MR, Sacci JB Jr, Richie TL. Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here? Trends Parasitol. 2009;25(11):525-533.
29. Amino R, et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat Med. 2006;12(2):220-224.
30. Hermsen CC, et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol. 2001; 118(2):247-251.
31. Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG. Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts. BMC Biotechnol. 2011;11:124.
32. Bejon P, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359(24):2521-2532.
33. Brochet X, Lefranc MP, Giudicelli V. IMGT/VQUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web server issue):W503-W508.
34. Vanderberg J, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004; 34(9):991-996.
35. Sacci JB Jr, et al. Mouse model for exoerythrocytic stages of Plasmodium falciparum malaria parasite. Proc Natl Acad Sci U S A. 1992;89(9):3701-3706.
36. Aide P, et al. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One. 2010;5(11):e13838.
37. Depraetere S, Verhoye L, Leclercq G, Leroux-Roels G. Human B cell growth and differentiation in the spleen of immunodeficient mice. J Immunol. 2001; 166(5):2929-2936.
38. van Schaijk BC, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One. 2008;3(10):e3549.
39. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology. 1989;98(pt 2):165-173.